PYPD Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -5.37%, SMA50 -4.25%, SMA200 14.35%). The stock’s 14-day RSI is 42.11 (neutral), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.58% below its high and over 83.48% above its low. Average 10-day trading volume of 295.88 thousand shares is significantly above the 3-month average of 132.88 thousand, indicating heightened recent market interest.

PolyPid Ltd. (NASDAQ:PYPD) closed at $5.21 USD, losing -$0.12 (-2.25%) from the previous close of $5.33. The stock is currently mid-range between its 52-week high and low $3.06 and $5.62. With a market capitalization of about $53.09 million, PolyPid Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.40). Key stats such as the average daily volume over the past year has been around 130.18 thousand shares, trading with heavier-than-usual volume. Headquartered in Petah Tikva, HM, PolyPid Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dikla Czaczkes Akselbrad, the company employs approximately 57 people and listed since June 26, 2020. PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions.

PolyPid Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.22. This means the shares are trading above this model’s fair value.

PolyPid Ltd. generated EPS of -$2.26 over the past year. Five-year average earnings growth is 14.14%. The latest quarter delivered EPS of -$0.35. The next quarter is forecast at -$0.43. Next year's EPS is expected at $16.17. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $9.00. The high target offers 149.52% upside. The low target suggests 72.74% downside. The mean target is $12.00. This offers 130.33% upside. PolyPid Ltd. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by -25.53%. The prior quarter beat by 20.59%. Over the last six quarters, Apple has recorded several small beats. These include 25.56% in February 12, 2025.

PolyPid Ltd. has 15.90 million shares outstanding. The public float is 8.76 million shares, elevated short interest at 0.27% of float. This equals 34.51 thousand shares. The short ratio is 0.52 days. Institutional investors hold 44.24% of the float. Insiders own 21.23%.

PolyPid Ltd. trades at a P/E ratio of -2.74, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 13.07 reflecting a rich premium to book value. The P/FCF stands at 0.0, also above market averages. Compared to sector medians, PolyPid Ltd. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

PolyPid Ltd. (NASDAQ:PYPD) shares are flat 2.76% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows PolyPid Ltd. trading at a premium to the broader market with a P/E of -2.74. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.60, suggesting 161.04% upside. Our AI forecast model points to short-term strength (6.91% over two weeks), a medium-term fall (-25.72% over three months), and a longer-term gain (156.05% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that PolyPid Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.91%, with price expected at $5.57 by July 22, 2026, within a range of $5.37 to $5.76 3-Month Outlook: Projected fall of -25.72%, reaching $3.87 by October 06, 2026, with a range of $3.70 to $4.02. 1-Year Outlook: Projected gain of 156.05%, with price at $13.34 by July 08, 2027, within a range of $2.97 to $20.20.